Abstract 2690
Background
GIST in older adults and in children are well-known entities, but this is not the case for AYA patients with GIST. Typically, GIST in children (70% female) rarely show mutations in KIT or platelet-derived growth factor receptor (PDGFR) (<15%), are often Succinate Dehydrogenase (SDH) deficient, are almost always located in the stomach (90%) and have a relatively indolent course of disease. The typical adult GIST (about 50% female) has mutations in KIT (75%) or PDGFR (15%), stomach as main location and an overall 5-years survival of 65% (SEER data). As data on AYA with GIST are very limited, we aimed to study the clinical and genetic characteristics and outcome of this specific group.
Methods
AYA GIST patients (18-40 years at diagnosis) diagnosed between 2009-2019 and registered in the Dutch GIST Registry (DGR) were included. Patients without mutations in KIT/PDGFR/BRAF and SDH deficiency (by immunohistochemistry) were considered quadruple wildtype (WT). Overall survival (OS) was estimated using Kaplan-Meier method. Furthermore, two subgroups were compared: 18-29 years vs. 30-40 years (Chi-square, Fisher’s exact, Mann-Whitney U test).
Results
From 1011 patients in the DGR, 52 AYA patients (5%) were identified: 54% male, median age 35 years. Main primary tumor locations were stomach (46%) and small intestine (46%). Four AYA patients had a known genetic predisposition: 2 Neurofibromatosis 1 (NF1), 1 Carney Triad, 1 KIT exon 11 germline mutation. GIST genetic profiles were reported as KIT mutation 64%, PDGFR mutation 6%, KIT/PDGFR WT 6%, quadruple WT 8%, SDH deficient 6% and NF1 associated 4%. At diagnosis, 42% had high-risk GIST and 13% metastatic disease.
With a median follow-up of 43 months (0-113), median OS for all patients was 8.9 years with a 5-year survival of 85%. No significant differences were found between the two subgroups with regard to gender, location, size, morphology, risk classification and mutation status.
Conclusions
GIST presenting at AYA age is rare. AYA GIST differ from the well-known paediatric GIST, but are also not fully similar to the typical adult GIST. In our series a remarkable high percentage of small intestine GIST and high-risk tumours were observed, 30% non-KIT/PDGFR mutations and a relatively good survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Netherlands Cancer Institute.
Funding
An unrestricted research grant for the Dutch GIST Registry was received from Novartis, Bayer and Pfizer.
Disclosure
I.M.E. Desar: Research grant / Funding (institution): Novartis; Advisory / Consultancy, advisory board: Eisai; Advisory / Consultancy, advisory board: Lilly. R.H.J. Mathijssen: Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Boehringer; Research grant / Funding (institution): Cristal Therapeutics; Honoraria (institution), Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pamgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi; Honoraria (institution): Servier. N. Steeghs: Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): AB science; Research grant / Funding (institution): Deciphera; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Merck Sharp & Dohme; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Merus. W.T.A. van der Graaf: Research grant / Funding (institution): Novartis; Advisory / Consultancy: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract